BeiGene declares OX40 agonist antibody

On September 13, BeiGene's BGB-A445 injection was applied for clinical application in China for the first time
.

From: CDE official website

According to the information disclosed by BeiGene, BGB-A445 (OX40 agonist antibody) is different from all other clinical OX40 antibodies.
It does not block the binding of OX40-OX40L and maintains the signal of antigen presenting cells OX40L.
The natural ligand stimulates OX40 to the maximum extent.
Activated, showing a wide range of single-agent efficacy in preclinical models including PD-1 resistance models
.

BGB-A445 mechanism of action

From: BeiGene official website

According to the Insight database, BGB-A445 has started phase I clinical trials abroad as early as December 2019, combined with tislelizumab for the treatment of advanced solid tumors
.

BGB-A445 global clinical trial registration

From: Insight database (http://db.
dxy.
cn/v5/home/)

OX40 target competition details

From: Insight database (http://db.
dxy.
cn/v5/home/)

OX40 is a type 1 transmembrane glycoprotein mainly expressed by T cells.
It is an important type of T cell costimulatory primer that can counteract immune cells (including T lymphocytes CD4+ and CD8+, NK cells and B lymphocytes).
Inhibit and directly stimulate effector T cells at the same time
.

At present, on a global scale, the research and development of new drugs for OX40 targets spans multiple types, including monoclonal antibodies, double antibodies, mRNA, etc.
; OX40 agonist antibodies are mainly used for the development of tumor indications, while inhibitor antibodies are mainly developed for the field of autoimmunity Treatment of disease
.

Since the beginning of this year, many blockbuster deals have been concluded in the field of OX40 antibodies, focusing on the field of OX40 inhibitors for the treatment of autoimmune diseases
.

In the field of oncology, there are currently no positive clinical data releases.

Note: The original text has been deleted